Survey of activated kinase proteins reveals potential targets for cholangiocarcinoma treatment

Exome sequencing of liver fluke–associated cholangiocarcinoma

(2012) Choon Kiat Ong et al.   NATURE GENETICS

A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study

(2011) Jun Ho Yi et al.   EUROPEAN JOURNAL OF CANCER

Overexpression of PDGFA and its receptor during carcinogenesis of Opisthorchis viverrini-associated cholangiocarcinoma

(2011) Sirintip Boonjaraspinyo et al.   PARASITOLOGY INTERNATIONAL

PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma

(2010) Watcharin Loilome et al.   INTERNATIONAL JOURNAL OF CANCER

Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial

(2009) C Bengala et al.   BRITISH JOURNAL OF CANCER

Myristoylated alanine-rich C kinase substrate phosphorylation promotes cholangiocarcinoma cell migration and metastasis via the protein kinase C-dependent pathway

(2009) Anchalee Techasen et al.   CANCER SCIENCE

Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2

(2009) Boris R. A. Blechacz et al.   HEPATOLOGY

Cholangiocarcinoma: lessons from Thailand

(2008) Banchob Sripa et al.   CURRENT OPINION IN GASTROENTEROLOGY